Predictors Evaluated for Microalbuminuria in Type 2 Diabetes
By LabMedica International staff writers Posted on 12 Mar 2020 |

Image: The Gen‐S hematology analyzer provides a complete blood count, a five-part differential leukocyte count, and a reticulocyte count (Photo courtesy of InCav).
Chronic inflammation has an important role in the development and progression of type 2 diabetes through immunologic inflammatory mechanisms. The neutrophil‐to‐lymphocyte ratio (NLR) is a new, simple, and inexpensive marker of subclinical inflammation and has been used as a systemic inflammatory marker in chronic diseases.
A symptom of nephropathy is albuminuria usually initiating with microalbuminuria, which was found to be a marker of vascular endothelial damage. Albuminuria is a well‐known predictor of poor renal outcomes in patients with type 2 diabetes and in essential hypertension and as such, it is important to monitor and diagnose in order to treat early.
A team of medical scientists working with the Ziv Medical Center (Safed, Israel) included in their study the data from 168 patients with type 2 diabetes mellitus (DM), which included patients aged ≥40 years old who had type 2 DM for at least four years. Patients were classified into three groups according to glycated hemoglobin (HbA1c) and microalbuminuria: Group A were patients with controlled diabetes; Group B were patients with uncontrolled diabetes (both groups without microalbuminuria); and Group C, were patients with uncontrolled diabetes with microalbuminuria.
The team examined the patients records regarding plasma glucose, HbA1c, creatinine, albumin, total cholesterol, triglycerides (TG), high‐density lipoprotein (HDL), and low‐density lipoprotein (LDL) levels in the venous blood samples obtained in the morning after 8‐hours fasting. Complete blood counts were analyzed in the hematology unit with a Beckman‐Coulter Gen‐S hematology analyzer (Beckman Coulter Inc., Brea, CA, USA). Mean platelet volume (MPV) and red blood cell distribution width (RDW) levels were gathered from patients' complete blood count, and NLR was calculated as the ratio of absolute number of neutrophil and lymphocyte counts.
The scientists reported that a significant difference in NLR was found between Group C and groups A and B. A statistically significant difference in RDW was found between groups B and C. Receiver operating characteristic curve analysis of inflammatory markers and microalbuminuria prediction showed an area under curve (AUC) of 0.675 for NLR and 0.614 for RDW. NLR value of 2.54 has 39.7% sensitivity, 78.8% specificity, and 45% positive predictive value (PPV). RDW value of 14.44% has 37.9% sensitivity, 76% specificity, and 41.5% PPV. TG/HDL ratio was lower in patients with controlled diabetes (group A) compared to the other two groups. Serum creatinine was higher as was the ratio to microalbumin in group C compared to the other two study groups.
The authors concluded that high levels of NLR were found in diabetic patients with microalbuminuria compared to controlled and uncontrolled patients without microalbuminuria. At the same time, they found high RDW values in patients with diabetes with microalbuminuria compared to diabetic patients without microalbuminuria. The study was published on February 25, 2020 in the Journal of Clinical Laboratory Analysis.
Related Links:
Ziv Medical Center
Beckman Coulter Inc
A symptom of nephropathy is albuminuria usually initiating with microalbuminuria, which was found to be a marker of vascular endothelial damage. Albuminuria is a well‐known predictor of poor renal outcomes in patients with type 2 diabetes and in essential hypertension and as such, it is important to monitor and diagnose in order to treat early.
A team of medical scientists working with the Ziv Medical Center (Safed, Israel) included in their study the data from 168 patients with type 2 diabetes mellitus (DM), which included patients aged ≥40 years old who had type 2 DM for at least four years. Patients were classified into three groups according to glycated hemoglobin (HbA1c) and microalbuminuria: Group A were patients with controlled diabetes; Group B were patients with uncontrolled diabetes (both groups without microalbuminuria); and Group C, were patients with uncontrolled diabetes with microalbuminuria.
The team examined the patients records regarding plasma glucose, HbA1c, creatinine, albumin, total cholesterol, triglycerides (TG), high‐density lipoprotein (HDL), and low‐density lipoprotein (LDL) levels in the venous blood samples obtained in the morning after 8‐hours fasting. Complete blood counts were analyzed in the hematology unit with a Beckman‐Coulter Gen‐S hematology analyzer (Beckman Coulter Inc., Brea, CA, USA). Mean platelet volume (MPV) and red blood cell distribution width (RDW) levels were gathered from patients' complete blood count, and NLR was calculated as the ratio of absolute number of neutrophil and lymphocyte counts.
The scientists reported that a significant difference in NLR was found between Group C and groups A and B. A statistically significant difference in RDW was found between groups B and C. Receiver operating characteristic curve analysis of inflammatory markers and microalbuminuria prediction showed an area under curve (AUC) of 0.675 for NLR and 0.614 for RDW. NLR value of 2.54 has 39.7% sensitivity, 78.8% specificity, and 45% positive predictive value (PPV). RDW value of 14.44% has 37.9% sensitivity, 76% specificity, and 41.5% PPV. TG/HDL ratio was lower in patients with controlled diabetes (group A) compared to the other two groups. Serum creatinine was higher as was the ratio to microalbumin in group C compared to the other two study groups.
The authors concluded that high levels of NLR were found in diabetic patients with microalbuminuria compared to controlled and uncontrolled patients without microalbuminuria. At the same time, they found high RDW values in patients with diabetes with microalbuminuria compared to diabetic patients without microalbuminuria. The study was published on February 25, 2020 in the Journal of Clinical Laboratory Analysis.
Related Links:
Ziv Medical Center
Beckman Coulter Inc
Latest Clinical Chem. News
- Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
- First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
- Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
- ‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
- Low-Cost Portable Screening Test to Transform Kidney Disease Detection
- New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
Channels
Clinical Chemistry
view channelMass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read more
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read moreMolecular Diagnostics
view channel
New Molecular Label to Help Develop Simpler and Faster Tuberculosis Tests
Tuberculosis (TB), the deadliest infectious disease globally, is responsible for infecting an estimated 10 million people each year and causing over 1 million deaths annually. While chest X-rays and molecular... Read more
Biomarker Discovery Paves Way for Blood Tests to Detect and Treat Osteoarthritis
The number of individuals affected by osteoarthritis is projected to exceed 1 billion by 2050. The primary risk factor for this common, often painful chronic joint condition is aging, and, like aging itself,... Read more
Liquid Biopsy Assay Detects Recurrence in CRC Patients Prior to Imaging
The detection of circulating tumor DNA (ctDNA) after treatment is a strong indicator of recurrence in colorectal cancer (CRC), but it often goes undetected due to the low traces of ctDNA present in the blood.... Read more
Ultra Fast Synovial Fluid Test Diagnoses Osteoarthritis and Rheumatoid Arthritis In 10 Minutes
Studies indicate that more than 50% of individuals aged 65 and older experience symptoms of osteoarthritis, while rheumatoid arthritis is a serious chronic condition affecting approximately 1 in 100 people... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read more
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read more
AI-Driven Analysis of Digital Pathology Images to Improve Pediatric Sarcoma Subtyping
Pediatric sarcomas are rare and diverse tumors that can develop in various types of soft tissue, such as muscle, tendons, fat, blood or lymphatic vessels, nerves, or the tissue surrounding joints.... Read more
AI-Based Model Predicts Kidney Cancer Therapy Response
Each year, nearly 435,000 individuals are diagnosed with clear cell renal cell carcinoma (ccRCC), making it the most prevalent subtype of kidney cancer. When the disease spreads, anti-angiogenic therapies... Read more
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read moreTechnology
view channel
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more